tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Illumina price target lowered to $124 from $126 at RBC Capital

RBC Capital lowered the firm’s price target on Illumina (ILMN) to $124 from $126 and keeps an Outperform rating on the shares as part of a broader research note on the Life Sciences Tools and Diagnostics sector. The firm is updating its model with “more realistic” multiples, the analyst tells investors in a research note. September isn’t a great month to own healthcare, and with a rebound still 2-3 quarters away, this isn’t the time to broadly own the sector, RBC added.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1